New data has come out to support the use of 160 mg aspirin per day in those who have been diagnosed and finished treatment for colorectal cancer. The research focused on those with mutations in PIK3 which represents about 30% of cases.
Aspirin was shown to effectively reduce recurrence rates and improve disease-free survival in those taking it over the 3-year period in these groups with stage II and stage III disease.
Severe side effects of daily low-dose aspirin use were rare. There was one case of severe gastrointestinal bleeding, one case of brain bleeding, and one allergic reaction.
Source:
https://ascopost.com/news/january-2025/new-findings-on-aspirin-and-risk-of-colorectal-cancer-recurrence